Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.17 USD | -1.50% | -5.17% | -46.22% |
14/05 | Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression | MT |
14/05 | Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.22% | 1.46B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.04% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- Neumora Therapeutics Q4 Loss Narrows